Posts Tagged ‘personalized cancer therapy’

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

Posted in Personalized and Precision Medicine & Genomic Research, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, tagged Advancing Precision Medicine, Cancer, multiomics platforms, oncology, personalized cancer therapy, precision oncology on October 4, 2025| Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

1:00 – 1:50

Lunch & Exhibits

TRACK 1 204BC

TRACK 2 204A

WIN SYMPOSIUM

MULTI-OMICS

1:50-4:05

SESSION 4

From Targets to Trials:
Translating Discovery into Impact

1:50-2:10

Beyond Checkpoint Inhibitors: Targeted Immunotherapeutic Approaches for the Management of Solid Tumors

Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University

2:10-2:30

Implementing Molecular Profiling in Early Phase Clinical Trials: Precision from Bench to Bedside

Apostolia M. Tsimberidou, MD, PhD, FASCO, FAAAS, Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer

2:30-2:40

Q&A

Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University

2:40-3:20

Non- CME Session: Venture Philanthropy

Eric Heil, MBA, Managing Partner, Medical Excellence Capital

John Lehr, President & CEO, Parkinson’s Foundation

Dr. Blaine Robinson, PhD, Vice President of the Therapy Acceleration Program (TAP), Blood Cancer United

3:20-4:10

eNSCLC Testing

Kurt A. Schalper, MD, PhD, Associate Professor of Pathology and Medicine (Medical Oncology), Yale School of Medicine; Director Translational Immuno-Oncology Laboratory, Yale Cancer Center

1:50-2:35

Non – CME Session: AI & Digital Pathology

Shruti Mathur, MS, Pharma Diagnostic Strategy Leader, Global Product Strategy (GPS), Genentech

Kimbery Gasaud,MBA, Principal Consultant, JK Life Sciences LLC

Paul Beresford, PhD, PathAI

Keith Wharton, Roche Diagnostics

2:35-3:50

Omics Into the Clinic – The Next Step

CHAIR: Sizun Jiang, PhD, Principal Investigator, Center for Virology & Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School

2:35-2:55

Arutha Kulasinghe, PhD, Associate Professor, Frazer Institute, University of Queensland; Founding Scientific Director, Queensland Spatial Biology Centre

2:55-3:10

Thazin Nwe Aung, MD
Associate Research Scientist in Pathology, Yale University

3:10-3:25

Ritu Mihani, PhD, Associate Director, Product Marketing, Akoya

3:25-3:50

Panel Discussion

CHAIR: Sizun Jiang, PhD, Principal Investigator, Center for Virology & Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School

Laura Dillon, PhD, Senior Director, Partnership Strategy Lead, External R&D and Innovation, AstraZeneca

Jared K. Burks, PhD, Director, Flow Cytometry & Cellular Imaging Core Facility MD, Anderson Cancer Center

Kurt Schalper, MD, PhD, Associate Professor, Pathology & Medical Oncology

Hoifung Poon, PhD, General Manager, Microsoft Research

4:10 – 4:25

Break and Exhibits

TRACK 1 204BC

TRACK 2 204A

WIN SYMPOSIUM

MULTI-OMICS

4:25-6:45

4:25-5:15

Transforming Pediatric Oncology: The Power of Precision Medicine

Giselle L. Sholler, MD, Division Chief, Pediatric Hematology/Oncology/BMT, Penn State Hershey Children’s Hospital; Professor, Pediatrics and Pharmacology; Founder & Chair, Beat Childhood Cancer Consortium

Wei Zhang, PhD, Hanes and Willis Family Professor in Cancer; Director, Cancer Genomics and Precision Oncology, Wake Forest Baptist Comprehensive Cancer Center

Elias Sayour, MD, PhD, Professor, Neurosurgery and Pediatrics; Assistant Dean, Clinical Research, UF College of Medicine, Program Co-leader, UF Health Cancer Center Immuno-Oncology and Microbiome (IOM) Program

Milan Radovich, PhD, Senior Vice President, Chief Scientific Officer, Caris Life Sciences

Pei Wang, PhD, Professor, Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai

Abigail Moore

5:15-5:25

Informing therapy decisions for improved patient care

Ashley Varghese, PharmD, RPh

5:25-5:50

Liquid Biopsies and Resistance Monitoring in Targeted Therapies

Pashtoon Kasi, MD, MS, Medical Director, GI Medical Oncology, City of Hope

5:50-6:10

Liquid Biopsies in Clinical Practice: Transforming Precision Oncology Through Molecular Monitoring

Hatim Husain, MD, Associate Professor, University of California, San Diego

Read Full Post »

Real Time Coverage Advancing Precision Medicine Annual Conference, Philadelphia PA November 1,2 2024

Posted in BioBanking, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Biomarkers & Medical Diagnostics, BioTechnology - Venture Creation, Venture Capital, Cancer Genomics, Cancer Informatics, Cardiovascular Pharmacogenomics, Circulating Tumor Cells (CTC), Computational Biology/Systems and Bioinformatics, Conference Coverage with Social Media, Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood, Personalized and Precision Medicine & Genomic Research, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Simulation Modeling in NGS, tagged Advancing Precision Medicine, Cancer Genomics, genomics, liquid biopsy, personalized cancer therapy, Personalized medicine, precision medicine, precision oncoogy, real time conference coverage on November 1, 2024| Leave a Comment »

Real Time Coverage Advancing Precision Medicine Annual Conference, Philadelphia PA November 1,2 2024

Reporter: Stephen J. Williams, Ph.D.

Source: https://www.advancingprecisionmedicine.com/apm-annual-conference-and-exhibition-in-philadelphia/

This event will be covered by the LPBI Group on Twitter. Follow on

using the following meeting hashtags

#AdvancingPM #precisionmedicine

The Advancing Precision Medicine (APM) Annual Conference 2024 will take place at the Pennsylvania Convention Center in Philadelphia, November 1-2, 2024. Located in the heart of the biopharma ecosystem and with easy access to some of the most renowned academic and research institutions in the world, the APM Annual Conference 2024 will attract all segments of the precision medicine landscape.

The event will consist of two parallel tracks composed of keynote addresses, panel discussions and fireside chats which will encourage audience participation. Over the course of the two-day event leaders from industry, healthcare, regulatory bodies, academia and other pertinent stakeholders will share an intriguing and broad scope of content.

his event will consist of three immersive tracks, each crafted to explore the multifaceted dimensions of precision medicine. Delve into Precision Oncology, where groundbreaking advancements are reshaping the landscape of cancer diagnosis and treatment. Traverse the boundaries of Precision Medicine Outside of Oncology, as we probe into the intricate interplay of genetics, lifestyle, and environment across a spectrum of diseases and conditions including rare disease, cardiology, ophthalmology, and neurodegenerative disease. Immerse yourself in AI for Precision Medicine, where cutting-edge technologies are revolutionizing diagnostics, therapeutics, and patient care. Additionally, explore the emerging frontiers of Spatial Biology and Mult-Omics, where integrated approaches are unraveling the complexities of biological systems with unprecedented depth and precision.

Whether you are a seasoned researcher, a dedicated clinician, or a visionary industry professional, this conference serves as a vibrant hub of knowledge exchange, collaboration, and innovation. Elevate your expertise, expand your network, and chart the course of your career trajectory amidst a community of like-minded individuals. Join us as we embark on this transformative journey, where the possibilities are as limitless as the potential of precision medicine itself.

Agenda – What’s on when

Day 1 – Friday, Nov 1

Day 2 – Saturday, Nov 2

November 01, 2024

7:30 – 8:25

Registration and Check-in Meeting Room 203 Philadelphia Convention Center

8:25 – 8:30

Welcome and Introduction

8:30 – 9:00

Opening Keynote

Advancing Precision Medicine in the Prevention and Treatment of Cardiometabolic Disease (CME Eligible)

Daniel Rader, Penn Medicine and Children’s Hospital of Philadelphia

9:00 – 10:20

9:00-10:20

Diagnosis to Treatment – A Case Study in Non Small Cell Lung Cancer

Moderator: Jason Crites, Assurance Health Data

Miriam Bredella, NYU Lagone Health

Rob Dumanois, Thermo Fisher Scientific

Joe Lennerz, BostonGene

9:00-9:20

Scaling Precision Therapeutic Development for Rare Disease (CME Eligible)Landscape Overview (CME Eligible)

Marni Falk, CHOP

9:20-9:40

Prognostic Biomarkers and Preclinical Modeling – the Cost of Inaction (CME Eligible)

Stephen Ekker, University of Texas at Austin

9:40-10:00

Regulatory Perspective on Rare Disease Drug Approvals and Efficacy Endpoints (CME Eligible)

Christine Nguyen, FDA

10:00-10:20

FDA’s Regulatory Flexibility Beyond One Positive Adequate & Well-Controlled Trial (CME Eligible)

Frank Sasinowski, Hyman, Phelps & McNamara

10:20 – 10:50

Networking, Exhibits and Product Presentations

10:25-10:35 PRODUCT PRESENTATION 204C

The Genexus Integrated Sequencer System:
NGS Results in 24 hours for Oncology Genomic Profiling

Jeff Smith, Thermo Fisher Scientific

10:35-10:45 PRODUCT PRESENTATION 204A

Shifting the Paradigm in Patient Management with MRD Testing: Why Evidence-Generated Performance and Experience is Key

Karen Lin, Natera

10:50 – 12:50

10:50-11:50

Who Needs Liquid Biopsy? Opportunities to Increase Access and Improve Outcomes

Nicole St. Jean, GSK

Phil Febbo, Veracyte, Inc.

Andrea Ferreira-Gonzalez, Virginia Commonwealth University

Lauren Leiman, BloodPAC

Nicole Sheahan, Global Colon Cancer Association

11:50-12:50

Advancing Digital Pathology and Precision Medicine – Where Are We Now?

Shruti Mathur, Genentech

Luke Benko, Roche Diagnostics

Kimberly Gasuad, JK Life Sciences

Eric Walk, PathAI

10:50-11:10

Real World Data vs Multi Modal Omics Data for Therapeutic Discovery (CME Eligible)

Adam Resnick, CHOP

11:10-11:30

An Academic Perspective on Rare Disease Target Discovery to Commercial Treatment Development (CME Eligible)

Hakon Hakonarson, CHOP

11:30-11:50

NCATS Perspective on Success and Failures of Drug Repurposing for Rare Disease (CME Eligible)

PJ Brooks, NIH

11:50-12:10

Pharma Perspective and Realities (CME Eligible)

Sundeep Dugar, Rarefy Therapeutics

12:10-12:50

A Panel Discussion: Scaling Precision Therapeutic Development for Rare Disease (CME Eligible)

Marni Falk, CHOP

Stephen Ekker, University of Texas at Austin

Christine Nguyen, FDA

Frank Sasinowski, Hyman, Phelps & McNamara

Adam Resnick, CHOP

Hakon Hakonarson, CHOP

Sundeep Dugar, Rarefy Therapeutics

PJ Brooks, NIH

12:50 – 1:50

Lunch & Product Presentations

1:10-1:25 PRODUCT PRESENTATION 204C

The Power of ctDNA Testing in Therapy Selection and Recurrence Monitoring

Taylor Jensen, LabCorp

1:50 – 3:50

1:50-3:50

Unlocking the Next Quantum Leap in Precision Medicine – A Town Hall Discussion (CME Eligible)

Co-Chairs

Amanda Paulovich, Fred Hutchinson Cancer Center

Henry Rodriguez, NCI/NIH

Eric Schadt, Pathos

Participants

Ezra Cohen, Tempus

Jennifer Leib, Innovation Policy Solutions

Susan Monarez, ARPA-H

Nick Seddon, Optum Genomics

Giselle Sholler, Penn State Hershey Children’s Hospital

Janet Woodcock, Former FDA

1:50-2:50

Advancing Precision Medicine in Non-Oncology Therapeutic Areas

Moderator: Mike Montalto, Amgen

Scott Friedman, Mt. Sinai

Sana Syed, University of Virginia

Lei Zhao, Amgen

2:50-3:20

Towards a Precision Neuroimmunology Platform (CME Eligible)

Amit Bar-Or, Penn Medicine

3:20-3:50

3:50 – 4:20

Networking and Exhibits

4:20 – 6:15

4:20-4:45

Precision Medicine, What’s So Difficult? The Interplay & Complexities of Delivering on the Promise of Precision Medicine (CME Eligible)

Sarah Hersey, BMS

4:45-5:30

Realizing Novel Treatment Paradigms with ctDNA-MRD (CME Eligible)

Mark Roschewski, NCI

5:30-6:30

The Potential Benefits of Next-day NGS for the Future of Precision Oncology

Allison Eck, Doylestown Health

Harry Erba, Duke Cancer Institute

Jeff Smith, Thermo Fisher Scientific

4:20-4:45

Advancing Precision Medicine: Polygenic Risk Scores and Beyond (CME Eligible)

Dokyoon Kim, Penn Medicine

4:45-5:30

The Rocky Road to Clinical Trial Diversity (CME Eligible)

Ysabel Duron, The Latino Cancer Institute

Porscha Johnson, PJW Clinical Pharmacy Consulting

Victor LaGroon, Department of Veterans Affairs

5:30-6:15

In the Rising Age of Women’s Health, How Do We Build Diagnostics to Last?

Oriana Papin Zoghbi, AOADx

Sarah Huah, Johnson & Johnson

6:30 – 7:00

Evening Keynote

Reimagining Health Equity in the Era of Precision Medicine (CME Eligible)

Rick Kittles, Morehouse School of Medicine

7:00 – 7:45

Cocktail Networking Reception

November 02, 2024

8:00-8:55

Registration and Check-in Meeting Room 203 Philadelphia Convention Center

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: International Cancer Clusters Showcase June 3 Philadelphia PA

Posted in BioTechnology - Venture Creation, Venture Capital, Cancer - General, Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Conference Coverage with Social Media, tagged Cancer, cancer vaccine, CART therapy, Glioblastoma, new precision-medicine drugs, personalized cancer therapy, precision oncoogy on June 3, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: International Cancer Clusters Showcase June 3, Philadelphia PA

Reporter: Stephen J. Williams PhD @StephenJWillia2

Updated on 07/08/2021

https://cancerdiscovery.aacrjournals.org/content/early/2021/07/01/2159-8290.CD-20-1741

Updated on 07/08/2021

https://medicalxpress.com/news/2021-07-cancer-wider-access-immunotherapy.html

Larry Blandford PharmD from Precision Medicine Group gave introduction about development of precision oncology medicine. Talked about value and value determination for partnerships.

Company Pitches:

Kernal Biologics: Preclinical immunotherapy company developing mRNA therapeutics. Their therapy only have activity in p53 deficient cells (messenger 2.0). They identified, by screening, multiple mRNAs that have oncoselectivity; ONC-333 is their lead mRNA active in AML and NSCLC. Looking for 5.5M seed $

Vaccibody AS: Vaccine technology from Oslo University to target antigen to antigen presenting cells. They are targeting the myocytes and dimerize the antigen to MHC. Targeting melanoma, certain cervical cancers, and hemotologic cancers. Technology based on identified neoantigens obtained from tumor biopsy.Three vaccines: VB10.neo VB10.16 against HPV cervical

Chimeric Therapeutics: developing CART to solid malignancies against CLEC14 (tumor endothelial marker), may make tumor susceptible to hypoxia. Targeting pancreatic cancer, prelim results in mice , efficacy of 15%, working on 3rd generation CART

Memo Therapeutics: Antibody therapeutics; based on Dropzylla single B cell sorting and subsequent screening for mAb. Targeting checkpoint inhibitors on solid tumors; have a new target other than PD1; target undisclosed on NK cells and T cells; Early stage have academic partners; seeking 20Million Swiss Francs

Takeda Oncology: Chris Hurff Senior Director Business Development; they depend on partnerships as they feel internal RD is less effective. They are diversifying their portfolio from small molecules. They have over 200 partnerships (132 in Boston). They are focusing on heme, lung, and Immunooncology. Partnering model: CEI (center external innovation) deals with both academic and small biotechs. They have numerous partners including Shatto and MD Anderson.

Read Full Post »

The 3rd STAT4ONC Annual Symposium: April 25-27, 2019 Hilton Hartford Connecticut

Posted in Artificial Intelligence in Medicine - Applications in Therapeutics, Cancer - General, Cancer and Current Therapeutics, Cancer Genomics, Clinical Diagnostics, Clinical Genomics, Genomic Testing: Methodology for Diagnosis, Health Economics and Outcomes Research, interventional oncology, Math, Precision Cancer Medicine, Scientific & Biotech Conferences: Press Coverage, tagged analysis, cancer genomics and therapy, clinical genomics, conference, Genome-wide analysis of gene expression, genomics, oncology, personalized cancer therapy, Statistics on February 26, 2019| Leave a Comment »

THE 3^RD STAT4ONC ANNUAL SYMPOSIUM APRIL 25-27, 2019, HILTON, HARTFORD, CONNECTICUT, 315 Trumbull St, Hartford, CT 06103

Reporter: Stephen J. Williams, Ph.D.

3.3.8 The 3^rd STATONC Annual Symposium, April 25-27, 2019, Hilton Hartford, CT, 315 Trumbull St., Hartford, CT 06103, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

SYMPOSIUM OBJECTIVES

The three-day symposium aims to bring oncologists and statisticians together to share new research, discuss novel ideas, ask questions and provide solutions for cancer clinical trials. In the era of big data, precision medicine, and genomics and immune-based oncology, it is crucial to provide a platform for interdisciplinary dialogues among clinical and quantitative scientists. The Stat4Onc Annual Symposium serves as a venue for oncologists and statisticians to communicate their views on trial design and conduct, drug development, and translations to patient care. To be discussed includes big data and genomics for oncology clinical trials, novel dose-finding designs, drug combinations, immune oncology clinical trials, and umbrella/basket oncology trials. An important aspect of Stat4Onc is the participation of researchers across academia, industry, and regulatory agency.

Meeting Agenda will be announced coming soon. For Updated Agenda and Program Speakers please CLICK HERE

The registration of the symposium is via NESS Society PayPal. Click here to register.

Live Coverage: MedCity Converge 2018 Philadelphia: AI in Cancer and Keynote Address

Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence Applications in Health Care, Big Data, BioIT: BioInformatics, Cancer - General, Cancer and Current Therapeutics, Cancer Informatics, Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, Conference Coverage with Social Media, Health Care System by Country, HealthCare IT, Immuno-Oncology & Genomics, Personalized and Precision Medicine & Genomic Research, tagged Artificial intelligence, Artificial Intelligence & Clinical Trials, Cancer immunotherapy, Conference Coverage with Social Media, Meeting Report, Personalized and Precision Medicine & Genomic Research, personalized cancer therapy on July 11, 2018| Leave a Comment »

Live Coverage: MedCity Converge 2018 Philadelphia: AI in Cancer and Keynote Address

Reporter: Stephen J. Williams, PhD

3.3.4 Live Coverage: MedCity Converge 2018 Philadelphia: AI in Cancer and Keynote Address, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

8:30 AM -9:15

Practical Applications of AI in Cancer

We are far from machine learning dictating clinical decision making, but AI has important niche applications in oncology. Hear from a panel of innovative startups and established life science players about how machine learning and AI can transform different aspects in healthcare, be it in patient recruitment, data analysis, drug discovery or care delivery.

Moderator: Ayan Bhattacharya, Advanced Analytics Specialist Leader, Deloitte Consulting LLP
Speakers:
Wout Brusselaers, CEO and Co-Founder, Deep 6 AI @woutbrusselaers ‏
Tufia Haddad, M.D., Chair of Breast Medical Oncology and Department of Oncology Chair of IT, Mayo Clinic
Carla Leibowitz, Head of Corporate Development, Arterys @carlaleibowitz
John Quackenbush, Ph.D., Professor and Director of the Center for Cancer Computational Biology, Dana-Farber Cancer Institute

Ayan: working at IBM and Thompon Rueters with structured datasets and having gone through his own cancer battle, he is now working in healthcare AI which has an unstructured dataset(s)

Carla: collecting medical images over the world, mainly tumor and calculating tumor volumetrics

Tufia: drug resistant breast cancer clinician but interested in AI and healthcareIT at Mayo

John: taking large scale datasets but a machine learning skeptic

moderator: how has imaging evolved?

Carla: ten times images but not ten times radiologists so stressed field needs help with image analysis; they have seen measuring lung tumor volumetrics as a therapeutic diagnostic has worked

moderator: how has AI affected patient recruitment?

Tufia: majority of patients are receiving great care but AI can offer profiles and determine which patients can benefit from tertiary care;

John: 1980 paper on no free lunch theorem; great enthusiasm about optimization algortihisms fell short in application; can extract great information from e.g. images

moderator: how is AI for healthcare delivery working at mayo?

Tufia: for every hour with patient two hours of data mining. for care delivery hope to use the systems to leverage the cognitive systems to do the data mining

John: problem with irreproducible research which makes a poor dataset: also these care packages are based on population data not personalized datasets; challenges to AI is moving correlation to causation

Carla: algorithisms from on healthcare network is not good enough, Google tried and it failed

John: curation very important; good annotation is needed; needed to go in and develop, with curators, a systematic way to curate medial records; need standardization and reproducibility; applications in radiometrics can be different based on different data collection machines; developed a machine learning model site where investigators can compare models on a hub; also need to communicate with patients on healthcare information and quality information

Ayan: Australia and Canada has done the most concerning AI and lifescience, healthcare space; AI in most cases is cognitive learning: really two types of companies 1) the Microsofts, Googles, and 2) the startups that may be more pure AI

Final Notes: We are at a point where collecting massive amounts of healthcare related data is simple, rapid, and shareable. However challenges exist in quality of datasets, proper curation and annotation, need for collaboration across all healthcare stakeholders including patients, and dissemination of useful and accurate information

9:15 AM–9:45 AM

Opening Keynote: Dr. Joshua Brody, Medical Oncologist, Mount Sinai Health System

The Promise and Hype of Immunotherapy

Immunotherapy is revolutionizing oncology care across various types of cancers, but it is also necessary to sort the hype from the reality. In his keynote, Dr. Brody will delve into the history of this new therapy mode and how it has transformed the treatment of lymphoma and other diseases. He will address the hype surrounding it, why so many still don’t respond to the treatment regimen and chart the way forward—one that can lead to more elegant immunotherapy combination paths and better outcomes for patients.

Speaker:
Joshua Brody, M.D., Assistant Professor, Mount Sinai School of Medicine @joshuabrodyMD

Director Lymphoma therapy at Mt. Sinai

lymphoma a cancer with high PD-L1 expression
hodgkin’s lymphoma best responder to PD1 therapy (nivolumab) but hepatic adverse effects
CAR-T (chimeric BCR and TCR); a long process which includes apheresis, selection CD3/CD28 cells; viral transfection of the chimeric; purification
complete remissions of B cell lymphomas (NCI trial) and long term remissions past 18 months
side effects like cytokine release (has been controlled); encephalopathy (he uses a hand writing test to see progression of adverse effect)

Vaccines

teaching the immune cells as PD1 inhibition exhausting T cells so a vaccine boost could be an adjuvant to PD1 or checkpoint therapy
using Flt3L primed in-situ vaccine (using a Toll like receptor agonist can recruit the dendritic cells to the tumor and then activation of T cell response); therefore vaccine does not need to be produced ex vivo; months after the vaccine the tumor still in remission
versus rituximab, which can target many healthy B cells this in-situ vaccine strategy is very specific for the tumorigenic B cells
HoWEVER they did see resistant tumor cells which did not overexpress PD-L1 but they did discover a novel checkpoint (cannot be disclosed at this point)

Please follow on Twitter using the following #hashtags and @pharma_BI

#MCConverge

#AI

#cancertreatment

#immunotherapy

#healthIT

#innovation

#precisionmedicine

#healthcaremodels

#personalizedmedicine

#healthcaredata

And at the following handles:

@pharma_BI

@medcitynews

Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

https://pharmaceuticalintelligence.com/press-coverage/

Read Full Post »

Medcity Converge 2018 Philadelphia: Live Coverage @pharma_BI

Posted in Artificial Intelligence Applications in Health Care, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Informatics, Cancer Prevention: Research & Programs, Clinical & Translational, Clinical Diagnostics, Evidence-based decision-making, Health Economics and Outcomes Research, Healthcare costs and reimbursement, Personalized and Precision Medicine & Genomic Research, Transformative Technologies in Healthcare, tagged healthcare, healthcare IT, healthcare models, personalised cancer therapy, personalised medicine, personalised treatment, Personalized and Precision Medicine & Genomic Research, personalized cancer therapy, precision medicine on July 11, 2018| Leave a Comment »

Medcity Converge 2018 Philadelphia: Live Coverage @pharma_BI

Stephen J. Williams: Reporter

3.3.3

3.3.3 Medcity Converge 2018 Philadelphia: Live Coverage @pharma_BI, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

MedCity CONVERGE is a two-day executive summit that gathers innovative thought leaders from across all healthcare sectors to provide actionable insight on where oncology innovation is heading.

On July 11-12, 2018 in Philadelphia, MedCity CONVERGE will gather technology disruptors, payers, providers, life science companies, venture capitalists and more to discuss how AI, Big Data and Precision Medicine are changing the game in cancer. See agenda.

The conference highlights innovation and best practices across the continuum—from research to technological innovation to transformations of treatment and care delivery, and most importantly, patient empowerment—from some of the country’s most innovative healthcare organizations managing the disease.

Meaningful networking opportunities abound, with executives driving the innovation from diverse entities: leading hospital systems, medical device firms, biotech, pharma, emerging technology startups and health IT, as well as the investment community.

Day 1: Wednesday, July 11, 2018

7:30 AM

2nd Floor – Paris Foyer

Registration + Breakfast

8:15 AM–8:30 AM

Paris Ballroom

Welcome Remarks: Arundhati Parmar, VP and Editor-in-Chief, MedCity News

8:30 AM–9:15 AM

Paris Ballroom

Practical Applications of AI in Cancer

9:15 AM–9:45 AM

Paris Ballroom

Opening Keynote: Dr. Joshua Brody, Medical Oncologist, Mount Sinai Health System

The Promise and Hype of Immunotherapy

Speaker:
Joshua Brody, M.D., Assistant Professor, Mount Sinai School of Medicine @joshuabrodyMD

9:45 AM–10:00 AM

Paris Foyer

Networking Break + Showcase

10:00 AM–10:45 AM

Paris Ballroom

The Davids vs. the Cancer Goliath Part 1

Startups from diagnostics, biopharma, medtech, digital health and emerging tech will have 8 minutes to articulate their visions on how they aim to tame the beast.

Start Time	End Time	Company
10:00	10:08	Belong.Life
10:09	10:17	Care+Wear
10:18	10:26	OncoPower
10:27	10:35	PolyAurum LLC
10:36	10:44	Seeker Health

Speakers:
Karthik Koduru, MD, Co-Founder and Chief Oncologist, OncoPower
Eliran Malki, Co-Founder and CEO, Belong.Life
Chaitenya Razdan, Co-founder and CEO, Care+Wear @_crazdan
Debra Shipley Travers, President & CEO, PolyAurum LLC @polyaurum
Sandra Shpilberg, Founder and CEO, Seeker Health @sandrashpilberg

10:45 AM–11:00 AM

Paris Foyer

Networking Break + Showcase

11:00 AM–11:45 AM

Montpellier – 3rd Floor

Breakout: Biopharma Gets Its Feet Wet in Digital Health

In the last few years, biotech and pharma companies have been leveraging digital health tools in everything from oncology trials, medication adherence to patient engagement. What are the lessons learned?

Moderator: Anthony Green, Ph.D., Vice President, Technology Commercialization Group, Ben Franklin Technology Partners
Speakers:
Derek Bowen, VP of Business Development & Strategy, Blackfynn, Inc.
Gyan Kapur, Vice President, Activate Venture Partners
Tom Kottler, Co-Founder & CEO, HealthPrize Technologies @HealthPrize

11:00 AM–11:45 AM

Paris Ballroom

Breakout: How to Scale Precision Medicine

The potential for precision medicine is real, but is limited by access to patient datasets. How are government entities, hospitals and startups bringing the promise of precision medicine to the masses of oncology patients

Moderator: Sandeep Burugupalli, Senior Manager, Real World Data Innovation, Pfizer @sandeepburug
Speakers:
Ingo Chakravarty, President and CEO, Navican @IngoChakravarty
Eugean Jiwanmall, Senior Research Analyst for Medical Policy & Technology Evaluation , Independence Blue Cross @IBX
Andrew Norden, M.D., Chief Medical Officer, Cota @ANordenMD
Ankur Parikh M.D, Medical Director of Precision Medicine, Cancer Treatment Centers of America @CancerCenter

11:50 AM–12:30 PM

Paris Ballroom

Fireside Chat with Michael Pellini, M.D.

Building a Precision Medicine Business from the Ground Up: An Operating and Venture Perspective

Dr. Pellini has spent more than 20 years working on the operating side of four companies, each of which has pushed the boundaries of the standard of care. He will describe his most recent experience at Foundation Medicine, at the forefront of precision medicine, and how that experience can be leveraged on the venture side, where he now evaluates new healthcare technologies.

Speaker:
Michael Pellini, M.D., Managing Partner, Section 32 and Chairman, Foundation Medicine @MichaelPellini

12:30 PM–1:30 PM

Chez Colette Restaurant – Lobby

Lunch Reception

1:30 PM–2:15 PM

Paris Ballroom

Clinical Trials 2.0

The randomized, controlled clinical trial is the gold standard, but it may be time for a new model. How can patient networks and new technology be leveraged to boost clinical trial recruitment and manage clinical trials more efficiently?

Moderator: John Reites, Chief Product Officer, Thread @johnreites
Speakers:
Andrew Chapman M.D., Chief of Cancer Services , Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital
Michelle Longmire, M.D., Founder, Medable @LongmireMD
Sameek Roychowdhury MD, PhD, Medical Oncologist and Researcher, Ohio State University Comprehensive Cancer Center @OSUCCC_James

2:20 PM–3:00 PM

Paris Ballroom

CONVERGEnce on Steroids: Why Comcast and Independence Blue Cross?

This year has seen a great deal of convergence in health care. One of the most innovative collaborations announced was that of Cable and Media giant Comcast Corporation and health plan Independence Blue Cross. This fireside chat will explore what the joint venture is all about, the backstory of how this unlikely partnership came to be, and what it might mean for our industry.

sponsored by Independence Blue Cross

Moderator: Tom Olenzak, Managing Director Strategic Innovation Portfolio, Independence Blue Cross @IBX
Speakers:
Marc Siry, VP, Strategic Development, Comcast
Michael Vennera, SVP, Chief Information Officer, Independence Blue Cross

3:00 PM–3:15 PM

Paris Foyer

Networking Break + Showcase

3:15 PM–4:00 PM

Montpellier – 3rd Floor

Breakout: Charting the Way Forward in Gene and Cell Therapy

There is a boom underway in cell and gene therapies that are being wielded to tackle cancer and other diseases at the cellular level. FDA has approved a few drugs in the space. These innovations raise important questions about patient access, patient safety, and personalized medicine. Hear from interesting startups and experts about the future of gene therapy.

Moderator: Alaric DeArment, Senior Reporter, MedCity News
Speakers:
Amy DuRoss, CEO, Vineti
Andre Goy, M.D., Chairman and Director of John Theurer Cancer Center , Hackensack University Medical Center

3:15 PM–4:00 PM

Paris Ballroom

Breakout: What’s A Good Model for Value-Based Care in Oncology?

How do you implement a value-based care model in oncology? Medicare has created a bundled payment model in oncology and there are lessons to be learned from that and other programs. Listen to two presentations from experts in the field.

Moderator: Mahek Shah, M.D., Senior Researcher, Harvard Business School @Mahek_MD
Speakers:
Charles Saunders M.D., CEO, Integra Connect
Mari Vandenburgh, Director of Value-Based Reimbursement Operations, Highmark @Highmark

4:00 PM–4:10 PM

Paris Foyer

Networking Break + Showcase

4:10 PM–4:55 PM

Montpellier – 3rd Floor

Breakout: Trends in Oncology Investing

A panel of investors interested in therapeutics, diagnostics, digital health and emerging technology will discuss what is hot in cancer investing.

Moderator: Stephanie Baum, Director of Special Projects, MedCity News @StephLBaum
Speakers:
Karen Griffith Gryga, Chief Investment Officer, Dreamit Ventures @karengg
Stacey Seltzer, Partner, Aisling Capital
David Shaywitz, M.D., Ph.D., Senior Partner, Takeda Ventures

4:10 PM–4:55 PM

Paris Ballroom

Breakout: What Patients Want and Need On Their Journey

Cancer patients are living with an existential threat every day. A panel of patients and experts in oncology care management will discuss what’s needed to make the journey for oncology patients a bit more bearable.

sponsored by CEO Council for Growth

Moderator: Amanda Woodworth, M.D., Director of Breast Health, Drexel University College of Medicine
Speakers:
Kezia Fitzgerald, Chief Innovation Officer & Co-Founder, CareAline® Products, LLC
Sara Hayes, Senior Director of Community Development, Health Union @SaraHayes_HU
Katrece Nolen, Cancer Survivor and Founder, Find Cancer Help @KatreceNolen
John Simpkins, Administrative DirectorService Line Director of the Cancer Center, Children’s Hospital of Philadelphia

5:00 PM–5:45 PM

Paris Ballroom

Early Diagnosis Through Predictive Biomarkers, NonInvasive Testing

Diagnosing cancer early is often the difference between survival and death. Hear from experts regarding the new and emerging technologies that form the next generation of cancer diagnostics.

Moderator: Heather Rose, Director of Licensing, Thomas Jefferson University
Speakers:
Bonnie Anderson, Chairman and CEO, Veracyte @BonnieAndDx
Kevin Hrusovsky, Founder and Chairman, Powering Precision Health @KevinHrusovsky

5:45 PM–7:00 PM

Paris Foyer

Networking Reception

Day 2: Thursday, July 12, 2018

7:30 AM

Paris Foyer

Breakfast + Registration

8:30 AM–8:40 AM

Paris Ballroom

Opening Remarks: Arundhati Parmar, VP and Editor-in-Chief, MedCity News

8:40 AM–9:25 AM

Paris Ballroom

The Davids vs. the Cancer Goliath Part 2

Startups from diagnostics, biopharma, medtech, digital health and emerging tech will have 8 minutes to articulate their visions on how they aim to tame the beast.

Start Time	End Time	Company
8:40	8:48	3Derm
8:49	8:57	CNS Pharmaceuticals
8:58	9:06	Cubismi
9:07	9:15	CytoSavvy
9:16	9:24	PotentiaMetrics

Speakers:
Liz Asai, CEO & Co-Founder, 3Derm Systems, Inc. @liz_asai
John M. Climaco, CEO, CNS Pharmaceuticals @cns_pharma
John Freyhof, CEO, CytoSavvy
Robert Palmer, President & CEO, PotentiaMetrics @robertdpalmer
Moira Schieke M.D., Founder, Cubismi, Adjunct Assistant Prof UW Madison @cubismi_inc

9:30 AM–10:15 AM

Paris Ballroom

Liquid Biopsy and Gene Testing vs. Reimbursement Hurdles

Genetic testing, whether broad-scale or single gene-testing, is being ordered by an increasing number of oncologists, but in many cases, patients are left to pay for these expensive tests themselves. How can this dynamic be shifted? What can be learned from the success stories?

Moderator: Shoshannah Roth, Assistant Director of Health Technology Assessment and Information Services , ECRI Institute @Ecri_Institute
Speakers:
Rob Dumanois, Manager – reimbursement strategy, Thermo Fisher Scientific
Eugean Jiwanmall, Senior Research Analyst for Medical Policy & Technology Evaluation , Independence Blue Cross @IBX
Michael Nall, President and Chief Executive Officer, Biocept

10:15 AM–10:25 AM

Paris Foyer

Networking Break + Showcase

10:25 AM–11:10 AM

Paris Ballroom

Promising Drugs, Pricing and Access

The drug pricing debate rages on. What are the solutions to continuing to foster research and innovation, while ensuring access and affordability for patients? Can biosimilars and generics be able to expand market access in the U.S.?

Moderator: Bunny Ellerin, Director, Healthcare and Pharmaceutical Management Program, Columbia Business School
Speakers:
Patrick Davish, AVP, Global & US Pricing/Market Access, Merck
Robert Dubois M.D., Chief Science Officer and Executive Vice President, National Pharmaceutical Council
Gary Kurzman, M.D., Senior Vice President and Managing Director, Healthcare, Safeguard Scientifics
Steven Lucio, Associate Vice President, Pharmacy Services, Vizient

11:10 AM–11:20 AM

Networking Break + Showcase

11:20 AM–12:05 PM

Paris Ballroom

Breaking Down Silos in Research

“Silo” is healthcare’s four-letter word. How are researchers, life science companies and others sharing information that can benefit patients more quickly? Hear from experts at institutions that are striving to tear down the walls that prevent data from flowing.

Moderator: Vini Jolly, Executive Director, Woodside Capital Partners
Speakers:
Ardy Arianpour, CEO & Co-Founder, Seqster @seqster
Lauren Becnel, Ph.D., Real World Data Lead for Oncology, Pfizer
Rakesh Mathew, Innovation, Research, & Development Lead, HealthShareExchange
David Nace M.D., Chief Medical Officer, Innovaccer

12:10 PM–12:40 PM

Paris Ballroom

Closing Keynote: Anne Stockwell, Cancer Survivor, Founder, Well Again

Finding Your Well Again

Anne Stockwell discusses her mission to help cancer survivors heal their emotional trauma and regain their balance after treatment. A multi-skilled artist as well as a three-time cancer survivor, Anne learned through experience that the emotional impact of cancer often strikes after treatment, isolating a survivor rather than lighting the way forward. Anne realized that her well-trained imagination as an artist was key to her successful reentry after cancer. Now she helps other survivors develop their own creative tools to help them find their way forward with joy.

Speaker:
Anne Stockwell, Founder and President, Well Again @annewellagain

12:40 PM–12:45 PM

Closing Remarks

Please follow on Twitter using the following #hashtags and @pharma_BI

#MCConverge

#cancertreatment

#healthIT

#innovation

#precisionmedicine

#healthcaremodels

#personalizedmedicine

#healthcaredata

And at the following handles:

@pharma_BI

@medcitynews

Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

https://pharmaceuticalintelligence.com/press-coverage/

Read Full Post »

Posts Tagged ‘personalized cancer therapy’

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025

WIN SYMPOSIUM

MULTI-OMICS

SESSION 4

From Targets to Trials: Translating Discovery into Impact

WIN SYMPOSIUM

MULTI-OMICS

Share this:

Like this:

Real Time Coverage Advancing Precision Medicine Annual Conference, Philadelphia PA November 1,2 2024

Agenda – What’s on when

November 01, 2024

Co-Chairs

Participants

November 02, 2024

Share this:

Like this:

Real Time Coverage @BIOConvention #BIO2019: International Cancer Clusters Showcase June 3, Philadelphia PA

Share this:

Like this:

THE 3RD STAT4ONC ANNUAL SYMPOSIUM APRIL 25-27, 2019, HILTON, HARTFORD, CONNECTICUT, 315 Trumbull St, Hartford, CT 06103

SYMPOSIUM OBJECTIVES

Other 2019 Conference Announcement Posts on this Open Access Journal Include:

Share this:

Like this:

Live Coverage: MedCity Converge 2018 Philadelphia: AI in Cancer and Keynote Address

3.3.4 Live Coverage: MedCity Converge 2018 Philadelphia: AI in Cancer and Keynote Address, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

8:30 AM -9:15

Practical Applications of AI in Cancer

9:15 AM–9:45 AM

Opening Keynote: Dr. Joshua Brody, Medical Oncologist, Mount Sinai Health System

Please follow on Twitter using the following #hashtags and @pharma_BI

Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

Share this:

Like this:

Medcity Converge 2018 Philadelphia: Live Coverage @pharma_BI

3.3.3 Medcity Converge 2018 Philadelphia: Live Coverage @pharma_BI, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

MedCity CONVERGE is a two-day executive summit that gathers innovative thought leaders from across all healthcare sectors to provide actionable insight on where oncology innovation is heading.

Day 1: Wednesday, July 11, 2018

7:30 AM

Registration + Breakfast

8:15 AM–8:30 AM

Welcome Remarks: Arundhati Parmar, VP and Editor-in-Chief, MedCity News

8:30 AM–9:15 AM

Practical Applications of AI in Cancer

9:15 AM–9:45 AM

Opening Keynote: Dr. Joshua Brody, Medical Oncologist, Mount Sinai Health System

9:45 AM–10:00 AM

Networking Break + Showcase

10:00 AM–10:45 AM

The Davids vs. the Cancer Goliath Part 1

10:45 AM–11:00 AM

Networking Break + Showcase

11:00 AM–11:45 AM

Breakout: Biopharma Gets Its Feet Wet in Digital Health

11:00 AM–11:45 AM

Breakout: How to Scale Precision Medicine

11:50 AM–12:30 PM

Fireside Chat with Michael Pellini, M.D.

12:30 PM–1:30 PM

Lunch Reception

1:30 PM–2:15 PM

Clinical Trials 2.0

2:20 PM–3:00 PM

CONVERGEnce on Steroids: Why Comcast and Independence Blue Cross?

3:00 PM–3:15 PM

Networking Break + Showcase

3:15 PM–4:00 PM

Breakout: Charting the Way Forward in Gene and Cell Therapy

3:15 PM–4:00 PM

Breakout: What’s A Good Model for Value-Based Care in Oncology?

4:00 PM–4:10 PM

Networking Break + Showcase

4:10 PM–4:55 PM

Breakout: Trends in Oncology Investing

4:10 PM–4:55 PM

Breakout: What Patients Want and Need On Their Journey

5:00 PM–5:45 PM

Early Diagnosis Through Predictive Biomarkers, NonInvasive Testing

From Targets to Trials:
Translating Discovery into Impact

THE 3^RD STAT4ONC ANNUAL SYMPOSIUM APRIL 25-27, 2019, HILTON, HARTFORD, CONNECTICUT, 315 Trumbull St, Hartford, CT 06103